IPO Trending
AKUMSEQ / NSE, BSEListed

Akums Drugs and Pharmaceuticals Limited

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a leading pharmaceutical CDMO providing end-to-end solutions in product development, manufacturing, R&D, regulatory dossier preparation, and testing for domestic and international markets. The company manufactures and sells branded drugs and APIs, with a diverse portfolio that includes tablets, capsules, liquids, injectables, eye drops, topicals, and even gummy bears. Akums has commercialized 4,025 formulations across more than 60 dosage forms and served 26 of India’s top 30 pharmaceutical companies by revenue in FY 2023. With 10 manufacturing units offering a combined annual capacity of 49.21 billion units and plans to commission two more by FY 2025, the company continues to scale its operations. Many of its facilities are accredited by global regulatory authorities such as EU-GMP, WHO-GMP, and US NSF. As of September 30, 2023, Akums employed 16,463 personnel, including 7,211 full-time and 9,252 contract staff.

₹646 - ₹67963.56x sub
Listed Price725.00
Listing Gain+6.77%
TimelineBookbuilding IPO
Open30 Jul 2024
Close01 Aug 2024
Allotment02 Aug 2024
Listing06 Aug 2024

Quota Reservation Portions

QIBPortion: 81,37,276 shares
53.67%
HNIPortion: 40,68,637 shares
26.83%
RetailPortion: 27,12,424 shares
17.89%
EmployeePortion: 2,43,902 shares
1.61%

Minimum Application Bracket Matrix

Retail1 lots / 22 shares
₹14,938
sHNI14 lots / 308 shares
₹2,09,132
bHNI67 lots / 1,474 shares
₹10,00,846

About the Company

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a leading pharmaceutical CDMO providing end-to-end solutions in product development, manufacturing, R&D, regulatory dossier preparation, and testing for domestic and international markets. The company manufactures and sells branded drugs and APIs, with a diverse portfolio that includes tablets, capsules, liquids, injectables, eye drops, topicals, and even gummy bears. Akums has commercialized 4,025 formulations across more than 60 dosage forms and served 26 of India’s top 30 pharmaceutical companies by revenue in FY 2023. With 10 manufacturing units offering a combined annual capacity of 49.21 billion units and plans to commission two more by FY 2025, the company continues to scale its operations. Many of its facilities are accredited by global regulatory authorities such as EU-GMP, WHO-GMP, and US NSF. As of September 30, 2023, Akums employed 16,463 personnel, including 7,211 full-time and 9,252 contract staff.

Company Promoters

Sanjeev JainSandeep JainAkums Master Trust
Akums Drugs and Pharmaceuticals Limited IPO Details | GMP, Allotment & Financials | IPO Trending